中科院武汉病毒研究所：发现对尼帕病毒有效的药物

Core Viewpoint - The research teams from Wuhan Institute of Virology have discovered that the oral nucleoside drug VV116 exhibits high efficacy in inhibiting the Nipah virus, providing new hope for the treatment of this high-mortality infectious disease [1][3][4]. Group 1: Research Findings - VV116 (Dihydroremdesivir) is a novel oral nucleoside antiviral drug that has been approved for the treatment of COVID-19 in Uzbekistan and China [3]. - The study published in the journal Emerging Microbes & Infections confirms that VV116 shows significant antiviral activity against the Nipah virus, including both Malaysian strain NiV-M and Bangladeshi strain NiV-B [3]. - In a lethal dose infection model using golden hamsters, VV116 administered at a dose of 400 mg/kg body weight increased the survival rate of the animals to 66.7% and significantly reduced viral loads in target organs such as the lungs, spleen, and brain [3]. Group 2: Public Health Implications - The Nipah virus has a high mortality rate of 40%-70% and has been a growing public health concern since its first outbreak in Malaysia in 1998, with increasing frequency and geographical spread of outbreaks in India and Bangladesh from 2023 to 2026 [2][4]. - The World Health Organization (WHO) has classified the Nipah virus as a regional threat of highest priority due to its wide host range and high fatality rate, with no approved drugs or vaccines currently available [2]. - VV116 not only serves as a potential preventive medication for high-risk groups such as healthcare workers and laboratory personnel but also provides a ready option for addressing current and future Nipah virus outbreaks [4].